Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe

Executive Summary

Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with FDA

You may also be interested in...



Generic Lipitor Era Dawns With Watson’s Launch, Followed By Ranbaxy’s Last-minute Approval

Teva will share in Ranbaxy’s profits during its exclusivity period, as FDA announces approval of Ranbaxy’s first-filed ANDA more than 14 hours after Watson discloses that it began shipping its atorvastatin “authorized generic”.

The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel